Eromonsele Idahosa, MD
Internal Medicine · Indianapolis, INNPI 1588659924
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 81 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by AstraZeneca at 30.0% of the total. 2025 is the largest year on record at $628, 2.2 times the $283 reported in 2019.
Across 81 payments — averaging $25.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$610
- Novo Nordisk$483
- AbbVie$302
- Lilly USA, LLC$219
- Amgen$131
- Shield Therapeutics Inc$62
- plus $227 from 7 others
Across 11 payments — averaging $53,635 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$558K
- Novartis$32K
What the payments were for
- Food & beverage$2,034100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 15 | $610 |
| Novo Nordisk | 12 | $483 |
| AbbVie(2 entities) | 24 | $302 |
| Lilly USA, LLC | 6 | $219 |
| Amgen(2 entities) | 7 | $131 |
| Shield Therapeutics Inc | 3 | $62 |
| Orexo US, Inc. | 4 | $58 |
| Phathom Pharmaceuticals, Inc. | 3 | $57 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $34 |
| Indivior Inc. | 2 | $31 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $16 |
| Redhill Biopharma Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,034 in reported general payments places this provider in the 80th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 18 | $34,966 |
| OzempicSemaglutide | 12 | $15,001 |
| LinzessLinaclotide | 18 | $14,234 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 67 | $7,037 |
| Pregabalin | 25 | $2,359 |
| Celecoxib | 13 | $2,116 |
| Desmopressin Acetate | 12 | $1,916 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 38 | $1,509 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 45 | $1,455 |
| Ofloxacin | 15 | $1,177 |
| Ibuprofen | 28 | $637 |
| Fluticasone Propionate | 24 | $628 |
| Cyclobenzaprine Hcl | 33 | $485 |
| Gabapentin | 45 | $483 |
| Rosuvastatin Calcium | 20 | $476 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $483 | $49,96730 claims |
| AbbVieLinzess | $302 | $14,23418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Indianapolis
- Raj VuppalanchiIndianapolis$279K
- Napoleon MamintaIndianapolis$116K
- Allon FriedmanIndianapolis$111K
- John AyresIndianapolis$107K
- Awaneesh KumarIndianapolis$68K
- Justin FieldIndianapolis$49K
- Misty ShieldsIndianapolis$39K
- Volodymyr OliynykIndianapolis$38K
- Sapan BhutaIndianapolis$30K
- Azizullah BeranIndianapolis$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.